Consensus $6.95. This update is driven by anticipated favorability in FY24 interest and other and diluted weighted average shares outstanding, due to continued strong cash flow generation, resulting in higher-than-expected cash balances, and the execution of a new $250M accelerated share repurchase program in the second quarter. Cardinal Health announced progress on the company’s ongoing business and portfolio review, including an updated enterprise operating and segment reporting structure, and an update to its fiscal year 2024 non-GAAP diluted earnings per share outlook. The company will host an analyst conference call today beginning at 8:30 a.m. where management will further discuss these announcements.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CAH:
- Early notable gainers among liquid option names on January 3rd
- Barclays starts healthcare technology, distribution with Neutral view
- Cardinal Health initiated with an Overweight at Barclays
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Foot Locker upgraded, Deckers downgraded: Wall Street’s top analyst calls
